0001193125-11-210747.txt : 20111114 0001193125-11-210747.hdr.sgml : 20111111 20110804192824 ACCESSION NUMBER: 0001193125-11-210747 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20110804 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMGEN INC CENTRAL INDEX KEY: 0000318154 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 953540776 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE STREET 2: MAIL STOP 24-1-B CITY: THOUSAND OAKS STATE: CA ZIP: 91320-1799 BUSINESS PHONE: (805)313-1762 MAIL ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE STREET 2: MAIL STOP 24-1-B CITY: THOUSAND OAKS STATE: CA ZIP: 91320-1799 FORMER COMPANY: FORMER CONFORMED NAME: AMGEN DATE OF NAME CHANGE: 19870305 CORRESP 1 filename1.htm SEC Letter
  650 Town Center Drive, 20th Floor
  Costa Mesa, California 92626-1925
  Tel: +1.714.540.1235   Fax: +1.714.755.8290
  www.lw.com
LOGO   FIRM /AFFILIATE OFFICES
  Abu Dhabi   Moscow
  Barcelona   Munich
  Beijing   New Jersey
  Boston   New York
  Brussels   Orange County
  Chicago   Paris
  Doha   Riyadh
  Dubai   Rome
August 4, 2011   Frankfurt   San Diego
  Hamburg   San Francisco
  Hong Kong   Shanghai
VIA EDGAR CORRESPONDENCE   Houston   Silicon Valley
  London   Singapore
Mr. Jim B. Rosenberg   Los Angeles   Tokyo
Senior Assistant Chief Accountant   Madrid   Washington, D.C.
Securities and Exchange Commission   Milan  

Division of Corporate Finance

100 F Street, N.E.

Washington, D.C. 20549

 

  Re: Amgen Inc.
    Form 10-K for the Year Ended December 31, 2010
    Filed February 25, 2011
    File No. 0-12477

Dear Mr. Rosenberg:

On behalf of Amgen Inc. (the “Company”), we are responding to your letter dated July 22, 2011 regarding the review of the above-referenced filings. Pursuant to our discussion today with Sasha Parikh, Staff Accountant, the Company hereby confirms that it intends to provide the Staff of the Division of Corporate Finance with the Company’s response to the Staff’s comments on or before August 19, 2011.

If you have any questions or comments with regard to this response or other matters, please call the undersigned at (714) 755-8245.

 

Very truly yours,

/s/ Charles K. Ruck

Charles K. Ruck

of LATHAM & WATKINS LLP

 

cc: Jonathan M. Peacock, Amgen, Inc.
  David J. Scott, Esq., Amgen Inc.
GRAPHIC 2 g217349g69u21.jpg GRAPHIC begin 644 g217349g69u21.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T- M#AT5%A$8(Q\E)"(?(B$F*S7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W M^/GZ_]H`"`$!```_`.F^"LDDO@$-([.WVN3ECD]%KOR0`23@#J37B-IK>H1^ M-K?QW)._]D:AJDFGA23M$6T*C?3@GZJ:];U_P]8>);!;+41,85D$@\J4QG(! M'4?4UYGX.\#:-JOB'Q);7;7C1Z9?"*W`NG&U>>O//05O?$Z]CT_5_"-Q/<>1 M;QZF&EU'P'J%KIFNVTUT_E[$AE^8XD4G&/;->A:8?^ M)3:$G_E@F2?]T5XU_;>H+XU3Q\9W_L>35CINW/R^3MVA_IU/U%>W9XS7BOP[ MUJ\M_B'+<74S-9>(I+D0;F)`=)"1^F1_P(4>,M:O9_B=;ZG!*XT[1K^VLGPQ M"L[$L_\`(@_05ZOXBUE=!T6:_8(60JJ!VP"S,`.F3QG/`S@&F>'=<&LV(DD: M#SMSX,+[DE0,5$B9YVDCK7&^#=1'AK5O&FE7I7MCIWB_P]'' M,9'LKQ$F4Q2%&(X8GI"8%%TX(+*"O-&OH?#6L2L MT.IVZWNG2N<@[ADID_0_BI]:Z/X62220^(_,=FVZW.!N.<#CBN5MH]!\0^-M M;LO'UW-'>1W12PMYYVBA6+)V[""!DC'UZ\UZE<36_AKP_'Y,3RP6BQ0HI?)* MY5!R>O6IWU%5UN+3/*):2W>?S,\`*RKC'_`OTKF-5^)-IHDQ6]T^9D:66.(V MSB1CY;E&+KQLR1D=<_A7'?#+QSI'A?PD-.U..]2X\]WPEJ[#!QCD?2NT\:>) M0OPYGU+34F:348EAM5V$/F3CIU!`R?PKE=1^'GBX>`FT5M9L9;.UA\U+5+3# MEERV`_7).1GWKO/`^LOKW@_3KZ8,)S$(Y@P(.]?E)_'&?QK"^'T;IXJ\:%D9 M0VI`J2,9^]TJ/XEVRW>M^$(I(!/$=4`D5DW*5^7.1Z4WXH^'M)MOA]J,MCH] MG%<*8MKP6RAQ^\7."!GI6IXLU>71/AK)<0*YN9+1((%126WNH48'MDG\*Y*X M^'7B[_A`3H9UBQ:TCA\P6@L_GW@[\;^N=W&:ZKPWXBEOOA<-5F#BYM;*190R MD-OC4C./?`/XUPTVC75A\'O#NN6D+_;M(N?M@7:_W2#^->G75I+KVDZ9>VUPMO=0E+N%I(]Z[BA!#+ MD9!#D=01U[56T+PQ<:3JTVI27D)-PA5[6"$I#'SG,>6)7)R3V)/0=_/OBM8Z MC:^,(WTV)S_PD%D+"4JI(R)%Z_AM%7?BG8W'AR+0=9TB)RUC#)IYV+GY&C(7 MIZ?-76:!&G@WX96K2QG-E8^=(@')&/!OC"\\)3,NLV5K#K@>X MN8)[/>Y\P70\-3:)?JRW>C7+VS;@1E%XW7X MN>+G9&"M';X8C@_*.AIWQDC>3P&ZHC.?M4/"C/>L^59_AEXK6Z@BD;PQK+_O MHT4D64Q_B`'13_+/H*TOC`#/\.;KR5,FZ6$C8,Y&\5L^*E9OA[JJA26.FR`` M#G_5FN+OO"UQK'PFT'4-/5H]8TBV2XMF48`1[@>M7_@S//=Z)K%Y< M0F&2YU.29E*D8+*I.,]JK^.O%/@S6(-0T6ZT^>]UB#?#!$EHQE$@R`58#IGG MKSZ&NA\.^'[^7X:V&BZK/)!=B%=S\,T1#[E'/!P`!^%7W\/Z@]U;7@UZ47<$ K;Q-+]FCQ(C,K8(Q@8VCD5H6&DVFGK+Y<2%YI7EDD*#